Globus Medical (GMED) Scheduled to Post Quarterly Earnings on Tuesday
Globus Medical (NASDAQ:GMED) is scheduled to be releasing its earnings data on Tuesday, April 29th. Parties interested in participating in the company’s conference call can do so using this link.
Globus Medical (NASDAQ:GMED) last released its earnings data on Wednesday, February 26th. The company reported $0.25 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.22 by $0.03. The company had revenue of $115.20 million for the quarter, compared to the consensus estimate of $114.96 million. During the same quarter last year, the company posted $0.22 earnings per share. Globus Medical’s revenue was up 14.6% compared to the same quarter last year. On average, analysts expect Globus Medical to post $0.93 EPS for the current fiscal year and $1.06 EPS for the next fiscal year.
Globus Medical (NASDAQ:GMED) opened at 23.03 on Monday. Globus Medical has a 1-year low of $14.53 and a 1-year high of $27.14. The stock has a 50-day moving average of $25.12 and a 200-day moving average of $21.64. The company has a market cap of $2.158 billion and a P/E ratio of 32.15.
A number of analysts have recently weighed in on GMED shares. Analysts at Zacks upgraded shares of Globus Medical from a “neutral” rating to an “outperform” rating in a research note on Tuesday, April 8th. They now have a $27.50 price target on the stock. On the ratings front, analysts at Piper Jaffray raised their price target on shares of Globus Medical from $26.00 to $28.00 in a research note on Thursday, February 27th. Finally, analysts at Leerink Swann raised their price target on shares of Globus Medical from $26.00 to $28.00 in a research note on Thursday, February 27th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $25.07.
Globus Medical, Inc (NASDAQ:GMED) is a medical device company focused on the design, development and commercialization of products that promote healing in patients with spine disorders.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.